Panadol Overview

Man experiencing pain relief after using Panadol products

Panadol is the No.1 pain relief brand* with 65 years of experience and expertise and is trusted by millions of consumers and HCPs in pain and fever.¹

Panadol in pain relief

Paracetamol

Globally, paracetamol or acetaminophen is one of the most used analgesic and antipyretic over-the-counter drugs.^2,3

Panadol for pain relief

Paracetamol is currently formulated as a single compound or as an active ingredient of multi-component preparations in combination with active ingredients⁴ to provide relief from fever and different types of pain (e.g. muscular and joint pains, headaches and migraines, and dysmenorrhoea).

Woman taking a Panadol paracetamol product for pain relief

Panadol’s suitability

Paracetamol, the active ingredient in Panadol, is suitable for 98% of the population,⁵ and is recommended across a broad range of patients including those with cardiovascular disease, dengue fever and COVID-19.^6–12 Panadol can be taken on an empty stomach, due to its favourable GI tolerability vs NSAIDs.¹³

In children, paracetamol’s GI tolerability is the same vs NSAIDs, with fewer drug-drug interactions than NSAIDs.^14,15

Innovative technology

Optizorb technology

Optizorb technology contains three main ingredients which are alginic acid, calcium carbonate and crospovidone that help speed the breakdown of paracetamol tablets in the stomach.^16,17

Learn more
Revolutionary bi-layer technology

Panadol has a unique bi-layer technology that uses two formulations – an immediate release layer on the outside of the caplet and a second underlying layer that delivers the remaining paracetamol for up to 8 hours of pain relief.¹⁸

Learn more
Paracetamol with caffeine

Panadol Extra contains caffeine, which acts as an analgesic adjuvant, by disrupting normal adenosine signaling by competitive inhibition. This in turn may contribute to or enhance the efficacy of other analgesics.¹⁹

Learn more

The Panadol range includes products with innovative technology and in combination with other ingredients such as caffeine manages mild to moderate pain.

Panadol offers a range of solutions for individual patient needs

Panadol Advance

Panadol Advance has five times faster disintegration and dissolution† and two times better absorption than standard paracetamol.²⁰

Panadol Extra

Dual “active” formulation that fights tough pains.^24-28

Panadol for children

Panadol for children contains paracetamol, which is recommended as first-line treatment for fever and mild-to-moderate pain in children.17-19

Panadol Joint

Immediate and controlled paracetamol release for extended pain relief for up to 8 hours.^32,33

Panadol Migraine

The powerful triple action of paracetamol, acetylsalicylic acid (aspirin) and caffeine working together to help combat migraine symptoms.^34,35

Panadol in practice

Grey-haired man smiling and walking with a stick

Joint pain & osteoarthritis

Based on the 2018 Global Pain Index (GPI), 92% of 24,000 people surveyed around the world suffered from some pain and 87% experienced joint pain.³⁶ Discover more about joint and osteoarthritic pain including signs and symptoms and, how to manage them.

Learn more

Fever

Fever is a common sign and symptom observed in a variety of clinical settings.³⁷ Discover more about fever in adults and children including how to assess fever, “red flag” symptoms and its management.

Learn more

Woman touching her forehead in pain with a headache

Headache disorders

Headache disorders, characterised by recurrent episode of headaches, are one of the most common disorders of the nervous system and, can be painful and disabling to sufferers.³⁸ Find out more about tension-type headaches and migraines, “red flag” symptoms and how to manage them.

Learn more

Footnotes

*Outside the USA and China †compared to standard paracetamol tablets . ^†when used as directed.

References

Nicholas Hall, 2019, Global CHC database D86.
Prescott LF. Am J Ther 2000;7:143-47.
Jóźwiak-Bębenista M & Nowak JZ. Acta Pol Pharm 2014;71(1):11–23.
Haleon. Available at https://www.haleon.com
GD Clarke et al. Int J Pharm Pract 2008;16(5):333–36.
Abdulla A et al. Age Ageing 2013;42(Suppl 1):i1-57.
AGS panel on persistent pain in older persons. J Am Geriatr Soc 2002;50(6 Suppl):S205–24.
Antman EM et al. Circulation 2007;115(12):1634–42.
WHO. Dengue guidelines for diagnosis, treatment, prevention and control. 2009. Available at: https://www.who.int/publications/i/item/9789241547871. Last accessed September 2022.
EMA. Press Release 18/03/20. Available at: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19. Last accessed September 2022.
NIH. COVID-19 Treatment Guidelines. Available at: https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf. Last accessed September 2022.
WHO. Clinical management of COVID-19. Available at: https://www.who.int/publications-detail-redirect/clinical-management-of-covid-19. Last accessed September 2022.
Panadol Optizorb Summary of product characteristics, February 2020.
Drugs.com. Acetaminophen drug-drug interactions. Available at: https://www.drugs.com/drug-interactions/acetaminophen.html. Last accessed September 2022.
Drugs.com. Ibuprofen drug-drug interactions. Available at: https://www.drugs.com/drug-interactions/ibuprofen.html. Last accessed September 2022.
Wilson CG et al. Drug Dev Ind Pharm 2011;37(7):747–53.
GlaxoSmithKline. GSK Data on File, Study A1900265.
GlaxoSmithKline. Panadol Osteo Product Information.
Derry CJ et al. Cochrane Database Syst Rev 2014;(12):CD009281.
Panadol Advance Clinical Overview. (GSK studies A1900279, A4000684, and A4000685) Panadol CSR Internal Documents Reference Sheet.
Kelly K et al. Pharm Res 2003;20(10):1668–73.
Graham GG, et al. Drug Saf 2005;28(3):227–40.
American College of Gastroenterology. Peptic Ulcer Disease. Available at: https://gi.org/topics/peptic-ulcer-disease/. Last accessed September 2022.
Migliardi JR et al. Clin Pharmacol Ther 1994;56:576–86.
Ali Z et al. Curr Med Res Opin 2007;23(4):841–51.
Rashwan WAM. J Periodontol 2009;80(6):945–52.
Pini LA et al. J Headache Pain 2008;9:367–73.
Pini LA et al. J Headache Pain 2012;13:669–75.
World Health Organization. Pocket book of hospital care for children: Guidelines for the management of common childhood illnesses, 2nd edition. 2013.
De Martino M & Chiarugi A. Pain Ther 2015;4:149–68.
National Institute for Health and Care Excellence. Fever in under 5s: assessment and initial management, 2013. Available at: https://www.nice.org.uk/guidance/cg160. Last accessed September 2022.
Dalton JT et al. Pharm Res 2001;18:1729–34.
Bacon TH et al. Br J Clin Pharmacol 2002;53(6):629–36.
Lipton RB et al. Arch Neurol 1998;55:210–17.
Silberstein SD. Neurology 2000;55:754.
GlaxoSmithKline. GSK Global Pain Index 3rd edition, 2018.
Steele GM et al. The Nurse Practitioner 2018;43(4):38-44.
World Health Organization. Headache disorders, 2016. Available at: https://www.who.int/news-room/fact-sheets/detail/headache-disorders. Last accessed September 2022.

Always read label before use . If you wish to report any adverse event , Product quality complaint or Medical enquiry please call on +973 16500404

This site is intended for UAE, Oman , Qatar , Bahrain , Kuwait , Lebanon and Jordan healthcare professionals only

PM-BH-PAN-24-00011c